BriaCell Therapeutics Corporation (BCTX) News

HUGE$ In BriaCell's Phase 2 clinical study, patients treated with the same Bria-IMT™ regimen formulation being used in the ongoing Phase 3 pivotal trial experienced a one-year survival rate of 55% (i.e. 55% of patients remain alive at least one year after starting on the study). This rate exceeds the survival data of the current standard of care for similar patients (see Table 1). Notably, 4 of 13 patients recruited in 2022 remain in survival follow-up as well, including:

Patient 01-009: Overall survival (OS) of 25 months has been reported in a patient who had failed 6 prior treatments prior to the BriaCell regimen. Stable disease and lymph node shrinkage has been recorded during 13 cycles of therapy.
Patient 07-001: OS of 24 months. She had stable disease and received 8 cycles of BriaCell's therapy.
Patient 16-003: OS of 15 months and received 8 cycles of therapy with stable disease. Prior to the BriaCell regimen, she had 7 lines of therapy, which included the progression of disease while on the antibody-drug conjugate (ADC) Enhertu.
Patient 11-018: OS of 14 months. This previously-reported responder with 100% resolution of her brain metastasis has recently completed her 19th cycle of therapy.

$BCTX No serious adverse events related to Bria-IMT™, 35 sites active and enrolling in pivotal Phase 3 study of Bria-IMT™, Pivotal Phase 3 study patient enrollment completion is expected in mid-2025

BIG NEWS https://feeds.issuerdirect.com/news-release.html?newsid=7546332967366263

BCTX...........................https://stockcharts.com/h-sc/ui?s=BCTX&p=W&b=5&g=0&id=p86431144783

BCTX.........................https://stockcharts.com/h-sc/ui?s=BCTX&p=W&b=5&g=0&id=p86431144783

BriaCell Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with “Eye-Bulging” Tumor

wainwright issues buy on bctx with $15 price $$$$$$$$$$$ cure 4 breast cancer? and others

Now the co has 8.5 mil for their business plan. Great for co. U got out and missed the push up as co has cure for breast cancer. Stock will rock

BCTX........................................https://stockcharts.com/h-sc/ui?s=BCTX&p=W&b=5&g=0&id=p86431144783

Gets out now millions of offering shares at .69…12,325,000 common shares. Each common share was sold at an offering price of $0.69 per share, for gross proceeds of approximately $8.5 million,

BCTX..................................https://stockcharts.com/h-sc/ui?s=BCTX&p=W&b=5&g=0&id=p86431144783

BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients

Sorry. Wrong Board.

BriaCell Therapeutics Announces $8.5 Million Offering

aks yourself why no BP wanted to be a part of this. Plenty of time to notice?

BCTX..........................https://stockcharts.com/h-sc/ui?s=BCTX&p=W&b=5&g=0&id=p86431144783

I'm predicting an offering this week... Company needs cash. Under $1m currently

BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer
Median overall survival of 15.6 months in Phase 2 Bria-IMT™ study patients treated in combination with immune checkpoint inhibitor
OS of 15.6 months compares favorably with 6.7-9.3 months reported for similar patients in the literature
Ongoing Phase 3 study investigating Bria-IMT™ in similar metastatic breast cancer population
No drug related discontinuations to date
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce positive overall survival data of its Phase 2 clinical study of Bria-IMT™ in combination with an immune check point inhibitor (CPI) in late stage metastatic breast cancer.
https://www.otcmarkets.com/stock/BCTX/news/story?e&id=2978177

Don’t blink

BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer

Good news and it goes lower again,,,lol

BCTX new 52 week low

BCTX new 52 week low

BCTX new 52 week low

BCTX under $2

BCTX new 52 week low

BCTX new 52 week low

BCTX. Under $3

$BCTX Shows “Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer”

Press Release: https://bit.ly/4aJmAoc

$BCTX #CancerTreatment #Innovation

Does anyone have information about the stock spinoff that occurred last year with this company? I have 600 shares of the spinoff security with 0 value and has remained that way since the spinoff. Thanks…

BCTX new 52 lo

BCTX new 52 lo

BCTX 10Q due March 13

BCTX new 52 week low

BCTX new 52 week low

$BCTX is thrilled to announce a new remarkable responder in our Phase 2 study of the Bria-IMT™ combination regimen. https://finance.yahoo.com/news/briacell-records-responder-remarkable-improvement-120000404.html

Good news today. I took a entry

BCTX new 52 week low

2023 Anticipated Milestones, please?

$BCTX $15 Price Target

Zacks Small-Cap Research just released a new report on BriaCell Therapeutics Corp. (Nasdaq: BCTX) with a $15 price target.

Read the full report here: https://scr.zacks.com/.../BCTX-Posters.../default.aspx

#Stocks #StocksToWatch #StockMarket

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) was featured in an article on Seeking Alpha
Discover more about this #BioTech company here: https://bit.ly/3DoEbUc
BriaCell Therapeutics: Fast-Tracking High-Potential Breast Cancer Immunotherapy
#Stocks #StocksToWatch

Strange stock, but I've loved having it the past couple of years. I've mostly day traded, as there was a pretty good pattern last year, of early drops and late charges, and vice versa. I did end up getting stuck at around $10 so have been holding a lot at that level. Hopefully it runs again and I can keep chipping away at my mortgage because of the fancy researchers in Vancouver. Best of luck, all!

Yep, I'm still here. She's getting ready to burst! Low float/high short interest, Fast track approval and now up on big volume. Gonna get interesting!

Under $4 by end of month

BriaCell Therapeutics Price Target Announced at $25.00/Share by HC Wainwright & Co.

BriaCell Reports Received FDA Fast Track Approval For Its Targeted Breast Cancer Immunotherapy

BCTX

I'm still here....wait til you see what happens this week

We will dance!

Closed above resistance of $10.50....We dance on Monday

Low float/high short interest. Setting up for big run

$BCTX BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/.

$BCTX announces the addition of Suzanne Ostrand-Rosenberg, Ph.D. to its Scientific Advisory Board.

Dr. Ostrand-Rosenberg has more than 40 years of experience leading investigations focused on the immune system’s response to cancer. She is currently the Robert & Jane Meyerhoff Professor of Biochemistry, Emeritus, and Professor of Biological Sciences, Emeritus, University of Maryland Baltimore County, Baltimore, MD, and has been working with the University since 1977. She was also appointed as the Adjunct Professor of Pathology, Huntsman Cancer Institute (HCI), University of Utah, Salt Lake City, UT, in 2018. https://finance.yahoo.com/news/briacell-adds-pioneering-immunologist-cancer-130000276.html

$BCTX has added Pioneering Immunologist and Cancer Immunotherapy Expert, Suzanne Ostrand-Rosenberg, Ph.D., to its Scientific Advisory Board!

Click here for a bio and to learn what she's bringing to the BriaCell team!

https://yhoo.it/3kbmmhX